objobjobj, page-4

You little beaut! Great find stilo and excellent post abdm. The small cap companies with innovative technology are now the big targets for 2011 upon expiration of the big pharma's patents.

I'm really liking this extract though:
""Big pharma's impoverished pipeline is forcing it to pay stunning prices for acquisitions and this is no secret. What is less evident is the way this neediness is changing the face of partnering. With more buyers in the market, including potential acquirers, pharma is under greater pressure not only to cut partnering deals that give biotechs a greater commercial presence, but also to grant biotechs more favorable licensing terms."

Really goes to show how hungry these vultures are now, patent expiry should see many success stories from little biotech companies. 2011 Will be the year of the Speculative biotech's. Companies with innovations that were never heard of by the big pharma's may now be a large blip on the radar, this should give the biotech sector a big shot in the arm. Exciting stuff.